AdvanCell is developing a portfolio of Targeted Alpha Therapies for the treatment of cancer.
Latest News
Dr. Oliver Sartor interviews AdvanCell CMO Dr. Anna Karmann on TheraPb Phase 2 for UroToday
Dr. Oliver Sartor interviews AdvanCell CMO Dr. Anna Karmann on TheraPb Phase 2 for UroToday
AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 2026
AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 2026
AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need
AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need
AdvanCell Announces Upcoming Presentation of TheraPb Phase 2 Expansion Study Design at ASCO Genitourinary Cancers Symposium 2026
AdvanCell Announces Upcoming Presentation of TheraPb Phase 2 Expansion Study Design at ASCO Genitourinary Cancers Symposium 2026
AdvanCell Receives First Delivery of High-Activity Thorium-228, Highlighting a Unique Industry Capability and Expertise Essential to Scaling Lead-212 Production for Targeted Alpha Therapies
AdvanCell Receives First Delivery of High-Activity Thorium-228, Highlighting a Unique Industry Capability and Expertise Essential to Scaling Lead-212 Production for Targeted Alpha Therapies
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer
AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth
AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth
TheraPb Phase 1b results featured by Urology Times in an interview with Principal investigator Aaron Hansen
TheraPb Phase 1b results featured by Urology Times in an interview with Principal investigator Aaron Hansen
Development Pipeline
Partners
Investors
